GlycoMimetics Board of Directors approves 1-for-100 reverse stock split ROCKVILLE, Md. / Jun 05, 2025 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC) (“GlycoMimetics”) today announced that its stockholders have approved the proposed merger (the “Merger”) with Crescent Biopharma, Inc. (“Crescent”), along with all proposals related to the Merger. The proposals were voted upon at GlycoMimetics’ special meeting in lieu of... Read More

Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors WALTHAM, Mass. , Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the... Read More

ROCKVILLE, Md. / Nov 06, 2024 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, on December 7-10, 2024. ASH Annual Meeting abstracts may be... Read More

Following closing, the combined company will advance Crescent’s portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors Crescent’s lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody incorporating the cooperative binding mechanism underpinning recent immuno-oncology breakthrough, expected to have preliminary proof of concept data in 2H26 Crescent pipeline also includes... Read More

ROCKVILLE, Md. / Oct 29, 2024 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the Phase 2 analysis of the adaptive Phase 2/3 study of uproleselan being conducted by the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology in adults with... Read More

After meeting with the U.S. Food and Drug Administration (FDA), it has been determined that the regulatory path forward for uproleselan in relapsed and refractory (R/R) Acute Myeloid Leukemia (AML) would require an additional clinical trial The Company will conduct a strategic review of the business seeking to maximize shareholder value, including the evaluation of potential business development opportunities for uproleselan... Read More

Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant unmet patient need Uproleselan demonstrated a clinically meaningful improvement in median overall survival (mOS) for patients with primary refractory AML; mOS was 31.2 months for the uproleselan arm compared to 10.1 months for the... Read More

ROCKVILLE, Md. / May 29, 2024 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company’s pivotal Phase 3 study of uproleselan in... Read More

Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect profiles of chemotherapy used in the study Comprehensive data analysis with medical, statistical, and regulatory experts underway and will be shared as appropriate; company will submit results for presentation at an upcoming medical... Read More

ROCKVILLE, Md. / Apr 25, 2024 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled... Read More

Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) to be reported in Q2 2024 New Drug Application (NDA) for uproleselan to be submitted to the U.S. Food and Drug Administration (FDA) by end of 2024 if outcome of R/R AML pivotal study is positive Phase 1a study of GMI-1687, a highly potent E-selectin antagonist with an initial focus on sickle cell disease (SCD),... Read More

ROCKVILLE, Md. / Mar 13, 2024 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance... Read More

ROCKVILLE, Md. / Feb 26, 2024 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44 th Annual Health Care Conference in Boston, MA on Monday, March 4, 2024 at 12:50 p.m. ET. A live webcast of the panel presentation will be available on the GlycoMimetics website at... Read More

ROCKVILLE, Md. / Feb 12, 2024 / Business Wire / GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant on February 6, 2024 of a non-qualified stock option award to purchase an aggregate of 130,000 shares of the Company’s common stock to Shantha Tyavanagimatt, Ph.D., the Company’s new Senior Vice President, Technical Operations.... Read More

First in human trial evaluating highly potent E-selectin antagonist, GMI-1687, met its primary and secondary endpoints with no dose-limiting toxicities or safety signals Single ascending dose study confirmed that subcutaneous dosing generated linear pharmacokinetics and achieved target plasma concentrations across all dosing levels GMI-1687 is being developed as a potential patient-controlled point-of-care treatment for... Read More

ROCKVILLE, Md. / Dec 10, 2023 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American Society of Hematology (ASH) Annual Meeting will feature two presentations on uproleselan, including an investigator-initiated trial (IIT) studying the first-in-class... Read More

ROCKVILLE, Md. / Nov 09, 2023 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference in London, UK on Thursday, November 16, 2023 at 1:30 p.m. GMT/8:30 a.m. ET. A live webcast of the fireside chat will be available on the GlycoMimetics website at... Read More

Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) on track to be reported by end of Q2 2024 NDA filing for uproleselan anticipated by end of 2024 pending outcome of R/R AML pivotal study Initial results for GMI-1687 Phase 1a study expected by end of Q1 2024 with initial focus to develop highly potent E-selectin antagonist as point-of-care treatment in sickle... Read More

ROCKVILLE, Md. / Oct 20, 2023 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter 2023 financial results on Friday, November 3, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the... Read More

GMI-1687, a highly potent E-selectin antagonist, is being developed as a potential point-of-care treatment for inflammatory diseases with initial focus on sickle cell disease (SCD) Single ascending dose study is expected to randomize approximately 40 healthy volunteers on GMI-1687 vs placebo with endpoints for safety, tolerability, and pharmacokinetics Initial results expected by end Q1 2024 ROCKVILLE, Md. / Sep 06, 2023 /... Read More

ROCKVILLE, Md. / Sep 05, 2023 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25 th Annual Global Investment Conference in New York, NY on Wednesday, September 13, 2023 at 11:30 a.m. ET. A live webcast of the presentation will be available on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations.... Read More

ROCKVILLE, Md. / Aug 17, 2023 / Business Wire / GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant on August 14 , 2023 of a non-qualified stock option award to purchase an aggregate of 110,000 shares to Gaetano Bonifacio, M.D., the Company’s new Vice President, Global Medical Affairs. The award was granted as an inducement... Read More

Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) expected by end of Q2 2024 after addition of time-based analysis option U.S. Food and Drug Administration (FDA) agrees to initial Pediatric Study Plan (iPSP) for uproleselan, and National Cancer Institute (NCI) agrees to sponsor pediatric Phase 1/2 study in acute AML First pediatric patient dosed in separate... Read More

ROCKVILLE, Md. / Jul 19, 2023 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter 2023 financial results on Wednesday, August 2, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the... Read More

ROCKVILLE, Md. / Jun 26, 2023 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023. Membership in... Read More

Final analysis to be conducted after the earlier of 295 survival events or the FDA-aligned cutoff date; topline results expected by the end of Q2 2024 Prolonged duration of blinded pooled survival in relapsed/refractory Acute Myeloid Leukemia expected to yield clinically mature dataset in Q2 2024, supporting addition of time-based analysis of overall survival primary endpoint Dataset is expected to reflect greater than three... Read More

ROCKVILLE, Md. / May 31, 2023 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 7, 2023 at 4:00 p.m. ET. A live webcast of the fireside chat will be available on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations . An... Read More

Pivotal Phase 3 study of uproleselan combined with cytarabine-based chemotherapy in relapsed/refractory (R/R) acute myeloid leukemia (AML) continues to be projected to reach final survival event trigger within first half of 2024 Cash and cash equivalents expected to fund current operations into late 4 th quarter of 2024 Conference call and webcast today at 8:30 a.m. ET ROCKVILLE, Md. / May 03, 2023 / Business Wire /... Read More

ROCKVILLE, Md. / Apr 26, 2023 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2023 financial results on Wednesday, May 3, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled... Read More

Significant progress in strengthening leadership, raising capital, and preparing for final results of the uproleselan Phase 3 study in relapsed/refractory (R/R) acute myeloid leukemia (AML) Interim utility analysis used high statistical threshold and resulted in independent Data Monitoring Committee (DMC) recommending trial continue to final survival events, projected to occur in the first half of 2024; DMC also expressed no... Read More

ROCKVILLE, Md. / Mar 01, 2023 / Business Wire / GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 43 rd Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2023 at 12:50 p.m. ET. A live webcast of the panel presentation will be available on the GlycoMimetics website at... Read More

ROCKVILLE, Md. / Feb 16, 2023 / Business Wire / GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant on February 10, 2023 of a non-qualified stock option award to purchase an aggregate of 150,000 shares to Chinmaya Rath, the Company’s new Senior Vice President and Chief Business Officer. The award was granted as an inducement... Read More

ROCKVILLE, Md. / Feb 06, 2023 / Business Wire / GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant on January 31 , 2023 of a non-qualified stock option award to purchase an aggregate of 100,000 shares to Debora Peralta, the Company’s new Vice President, Commercial Operations. The award was granted as an inducement equity... Read More

ROCKVILLE, Md.--( BUSINESS WIRE )-- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced results from two investigator-sponsored trials studying uproleselan in patients with acute myeloid leukemia (AML). These results were presented at the 64 th American Society of Hematology (ASH) Annual... Read More